HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
The Week

Replimune melanoma drug wins support of FDA panel

The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.

By BioPharma Dive · Jul 30, 2026 · via BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Shionogi makes the call on COVID pill Xocova TV spot
Shionogi's "Got the Call, Make the Call" campaign for COVID antiviral Xocova kicks off with a TV ad depicting …
Jul 31, 2026
The WeekFierceBiotech ↗
Apnimed's IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sle…
Jul 31, 2026
FDA Sets FY 2027 PDUFA Fees, With Slightly Lower Application and Program Charges
The WeekBriefing
FDA Sets FY 2027 PDUFA Fees, With Slightly Lower Application and Program Charges
FDA’s July 30 notice sets FY 2027 PDUFA fees below FY 2026 levels for clinical-data applications, non-clinical…
Jul 31, 2026